Construction method of specific chromatogram of tendon-expanding and blood-activating powder and specific chromatogram thereof

Through the combination of high-performance liquid chromatography and mass spectrometry, a characteristic map of Zhanjin Huoxue San was constructed, which solved the problem of lack of overall component quality detection in the existing technology, and achieved accurate monitoring of multiple components of the Chinese patent medicine, improving the The quality control of medicinal materials and Chinese patent medicines is ensured to ensure the safety and consistency of clinical medicines.

CN119064500APending Publication Date: 2024-12-03SHAANXI UNIV OF SCI & TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411193586.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a lack of effective quality detection methods in the prior art to evaluate the overall component information of Zhanjin Huoxue San, and it is impossible to accurately monitor the quality of various components of the Chinese patent medicine, which affects its clinical efficacy and safety.

Method used

High performance liquid chromatography (HPLC) combined with mass spectrometry, and ultrasonic extraction and methanol solution were used to construct a characteristic map of Zhanjin Huoxue San, and 11 common peaks were identified and confirmed, including ginseng, amber, myrrh, frankincense, and blood exhaustion. The characteristic components of medicinal materials such as Panax notoginseng form a full-view map for quality monitoring.

Benefits of technology

Accurate, rapid and comprehensive quality monitoring of multiple characteristic components of Zhanjin Huoxue San has been achieved, and the quality control level of medicinal materials and Chinese patent medicines has been improved, ensuring the safety and consistency of clinical medicines, simplifying the testing process, and saving time and cost.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005015742620000031
    Figure BDA0005015742620000031
  • Figure BDA0005015742620000091
    Figure BDA0005015742620000091
  • Figure BDA0005015742620000101
    Figure BDA0005015742620000101
Patent Text Reader

Abstract

According to the construction method of the specific chromatogram of the sinew-spreading and blood-activating powder and the specific chromatogram of the sinew-spreading and blood-activating powder, the sinew-spreading and blood-activating powder is detected through combination of high performance liquid chromatography and mass spectrometry, 11 common peaks can be identified at the same time by systematically and reasonably controlling chromatographic conditions, and the complete specific chromatogram of the sinew-spreading and blood-activating powder is formed. The specific chromatogram and the method constructed by the invention are high in precision, good in reproducibility, accurate and reliable, and capable of quickly and comprehensively monitoring the quality of a plurality of characteristic components of the sinew-expanding and blood-activating powder, so that the quality control level of ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica sinensis, pseudo-ginseng, artificial musk and artificial bezoar medicinal materials is improved, and the quality of the sinew-expanding and blood-activating powder is improved. The internal quality of the tendon-expanding and blood-activating powder is improved; the quality consistency of ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica sinensis, pseudo-ginseng, artificial musk and calculus bovis factitius medicinal materials and the tendon-expanding and blood-activating powder is kept, and raw materials meeting the requirements of the tendon-expanding and blood-activating powder are provided clinically.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of quality control management of compound traditional Chinese medicine preparations, and specifically relates to a method for constructing a characteristic spectrum of Zhanjin Huoxue Powder and its characteristic spectrum. Background Art

[0002] Zhanjin Huoxue San (National Medicine Standard Z61021521) is a Chinese patent medicine mainly used to treat traumatic injuries and other chronic tissue injuries, such as lumbar muscle strain, joint contusion, frozen shoulder, cervical spondylosis and lumbar disc herniation. Its main effects include promoting blood circulation and removing blood stasis, unblocking meridians and stretching muscles, and relieving swelling and pain. The uniqueness of Zhanjin Huoxue San lies in its exquisite formula, which brings together the essence of many Chinese medicinal materials. Each medicinal material has been carefully selected and proportioned to ensure that its efficacy can be maximized. Its ingredients are rich and diverse, covering many Chinese medicinal materials such as ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica, Panax notoginseng, artificial musk and artificial bezoar. These medicinal materials each carry unique pharmacological effects, synergistically enhance the therapeutic effect. As a treasure among traditional Chinese medicinal materials, ginseng can not only replenish qi and blood, enhance physical strength, but also harmonize the functions of internal organs and provide comprehensive nourishment for the body. Amber has the effects of calming the nerves and relieving shock, promoting blood circulation and removing blood stasis. It can help patients calm their minds, reduce anxiety, promote blood circulation, and relieve blood stasis symptoms. Frankincense and myrrh are good medicines for reducing swelling and relieving pain. They can quickly relieve the swelling and pain symptoms caused by traumatic injuries or other reasons, and relieve the pain of patients. Angelica and Panax notoginseng can promote blood circulation and remove blood stasis, relax muscles and tendons, and have significant effects on the treatment of chronic tissue injuries such as traumatic injuries and lumbar muscle strain. In addition, pearl powder has the effects of calming the nerves, clearing away heat and detoxifying, while artificial musk and artificial bezoar have the effects of awakening the mind, reducing swelling and detoxifying. The synergistic effect of these medicinal materials makes Zhanjin Huoxue Powder have significant therapeutic effects in the treatment of traumatic injuries, joint muscle swelling and pain, etc.

[0003] In summary, the fine formula of Zhanjin Huoxue Powder and the synergistic effect between the medicinal materials give it a unique advantage in the treatment of chronic tissue injuries such as traumatic injuries. It can not only relieve the patient's pain symptoms, but also promote the repair and regeneration of damaged tissues, helping patients recover as soon as possible. The pharmacological mechanism of Zhanjin Huoxue Powder is mainly reflected in promoting blood circulation and reducing swelling and relieving pain. The various medicinal materials in its ingredients have the effect of dilating blood vessels and increasing local blood supply, thereby relieving pain and inflammatory reactions. At the same time, some medicinal materials also have anti-inflammatory and analgesic effects, which can reduce the symptoms of redness, swelling and pain caused by tissue damage.

[0004] Currently, there are few quality inspection methods for Zhanjin Huoxue Powder, and most of them are studies on the ingredients of a single herb in the prescription, which cannot reflect the overall ingredient information of Zhanjin Huoxue Powder. Summary of the invention

[0005] The purpose of the present invention is to solve the shortcomings of the prior art and provide a method for constructing a characteristic spectrum of Zhanjin Huoxue Powder and its characteristic spectrum, which can simultaneously detect multiple components of Zhanjin Huoxue Powder. This method can accurately, clearly and objectively evaluate the quality of Zhanjin Huoxue Powder, and plays an important role and value in controlling the quality of Zhanjin Huoxue Powder and ensuring clinical efficacy.

[0006] The present invention is achieved through the following technical solutions:

[0007] The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder comprises the following steps:

[0008] S1. Take the contents of Zhanjin Huoxue Powder, add methanol, and perform ultrasonic extraction to obtain a test solution;

[0009] S2, dissolving ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, rutin, notoginsenoside R1, hyperoside, rutin, resveratrol, 11-carbonyl-β-acetyl boswellic acid in methanol to obtain a single reference solution;

[0010] S3, injecting the test solution in S1 and the reference solution in S2 into a high performance liquid chromatograph for chromatographic analysis, and recording the chromatograms of the test solution and the reference solution;

[0011] S4, performing high-resolution mass spectrometry analysis on the test solution to obtain a total ion current diagram, importing the total ion current diagram into Xcalibur software, performing data analysis based on the peaks of the chromatogram of the test solution, and obtaining mass spectrum result diagrams of each chemical component;

[0012] S5. According to the chromatogram of the test solution and the chromatogram of the single reference solution, the chemical composition of each peak in the chromatogram of the test solution is determined in combination with the total ion current diagram and the mass spectrum of the chemical components to obtain a characteristic spectrum.

[0013] Preferably, the ultrasonic extraction time is 30 min-1 h.

[0014] Preferably, in S3, the liquid chromatography conditions are: the chromatographic column is a Shim-pack VP-ODS chromatographic column; and the detection wavelength of the detector is 210 nm.

[0015] Preferably, in S3, the liquid chromatography conditions are: the mobile phase is acetonitrile-0.1% phosphoric acid aqueous solution.

[0016] Preferably, in S3, the liquid chromatography conditions are: gradient elution, and the elution procedure is shown in the following table:

[0017]

[0018] Preferably, the method further includes: importing the chromatograms of the test solutions of different batches of Zhanjin Huoxue Powder obtained in S3 into a Chinese medicine chromatographic characteristic spectrum similarity evaluation system and performing similarity analysis to confirm the reliability of the results.

[0019] Furthermore, the chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San obtained in S3 are imported into the Chinese medicine chromatographic characteristic spectrum similarity evaluation system and similarity analysis is performed to confirm the reliability of the results, specifically: the chromatograms of the test solutions and reference solutions of different batches of Zhan Jin Huo Xue San obtained in S3 are imported into the Chinese medicine chromatographic characteristic spectrum similarity evaluation system; the chromatographic peaks existing in the chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San are selected as common peaks, and the reference spectrum of Zhan Jin Huo Xue San is generated by the average value calculation method, and the relative retention time and relative peak area of ​​each common peak are calculated; after data import, multi-point correction and data matching, similarity analysis is performed; the similarity result table between the chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San and the common peak pattern is obtained and exported; the reliability of the result is confirmed based on the similarity result table and the chromatogram of the test solution of Zhan Jin Huo Xue San.

[0020] Preferably, in S4, the high-resolution mass spectrometry detection conditions are: electrospray ionization, spray voltage 3500V, sheath gas flow rate 40arb, auxiliary gas flow rate 10arb, capillary temperature 300°C, auxiliary gas temperature 300°C, scanning mode is full scan mode, and the mass-to-charge ratio scanning range m / z is 100-1300.

[0021] Preferably, in S5, according to the chromatogram of the test solution and the chromatogram of the single reference solution obtained in S3, in combination with the total ion flow diagram obtained by high-resolution mass spectrometry and the mass spectrum of the chemical components, resveratrol is used as the reference peak, and peak 9 in the chromatogram is identified as rutin, peak 10 as hyperoside, peak 11 as isoquercetin, peak 12 as notoginsenoside R1, peak 16 as ginsenoside Rg1, peak 31 as dragon's blood A, peak 34 as pterostilbene, peak 37 as dehydrocostus lactone, peak 39 as inulin lactone, and peak 53 as 11-carbonyl-β-acetylboswellic acid, to obtain the characteristic spectrum of Zhanjin Huoxue Powder.

[0022] The present invention also provides a characteristic spectrum of Zhanjin Huoxue Powder constructed by the method as described above.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] The present invention uses high performance liquid chromatography (HPLC) combined with mass spectrometry to detect Zhanjin Huoxue Powder, and by systematically and reasonably controlling the chromatographic conditions, 11 common peaks can be identified at the same time, forming the overall picture of the characteristic spectrum of Zhanjin Huoxue Powder, and achieving the purpose of controlling the original medicinal materials in Zhanjin Huoxue Powder. The present invention introduces the characteristic spectrum of ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica, Panax notoginseng, artificial musk and artificial bezoar reference medicinal materials for research, and studies the components common to the reference medicinal materials and Zhanjin Huoxue Powder, and uses them as the basis for determining the characteristic spectrum peaks. Eleven characteristic components were identified by high performance liquid chromatography and related reference substances, which can be used to characterize the medicinal flavors of Blood Dracaena, Panax notoginseng, ginseng, myrrh and frankincense. They are: resveratrol (peak 17), dragon's blood A (peak 31), and pterostilbene (peak 34) derived from Blood Dracaena; rutin (peak 9), hyperoside (peak 10), isoquercetin (peak 11), and notoginsenoside R1 (peak 12) derived from Panax notoginseng; ginsenoside Rg1 (peak 16) derived from ginseng; dehydrocostus lactone (peak 37) and inulin lactone (peak 39) derived from myrrh; and 11-carbonyl-β-acetylboswellic acid (peak 53) derived from frankincense. The characteristic spectrum and method constructed by the present invention have high precision, good reproducibility, accuracy and reliability, and can quickly and comprehensively monitor the quality of multiple characteristic components of Zhanjin Huoxue Powder, which not only improves the quality control level of ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica, Panax notoginseng, artificial musk and artificial bezoar medicinal materials, but also improves the intrinsic quality of Zhanjin Huoxue Powder; maintains the consistency of the quality of ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica, Panax notoginseng, artificial musk and artificial bezoar medicinal materials with Zhanjin Huoxue Powder, provides raw materials that meet the requirements of Zhanjin Huoxue Powder for clinical use, and provides a guarantee for the safety of Zhanjin Huoxue Powder. The method for constructing the characteristic spectrum of the present invention is simple and easy, has good reproducibility, is accurate and reliable, and at least 11 components are confirmed at one time under the same chromatographic conditions, saving time, saving inspection costs, and improving detection efficiency. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0026] Figure 1 This is the HPLC characteristic spectrum of Zhanjin Huoxue Powder;

[0027] Figure 2 This is a chromatogram obtained by optimizing the extraction method during the preparation of the test solution of the present invention;

[0028] Figure 3This is a chromatogram obtained by optimizing the extraction solvent during the preparation of the test solution of the present invention;

[0029] Figure 4 This is a chromatogram obtained by optimizing the extraction time during the preparation of the test solution of the present invention;

[0030] Figure 5 The chromatogram obtained by optimizing the detection wavelength under the chromatographic conditions of the present invention;

[0031] Figure 6 The chromatogram obtained by optimizing the column temperature in the chromatographic conditions of the present invention;

[0032] Figure 7 The chromatogram obtained by optimizing the mobile phase composition under the chromatographic conditions of the present invention;

[0033] Figure 8 A chromatogram obtained by optimizing the elution procedure in the chromatographic conditions of the present invention;

[0034] Fig. 9 is the resveratrol chromatogram of the present invention;

[0035] Fig.10 is the rutin chromatogram of the present invention;

[0036] Fig.11 is the chromatogram of hyperoside of the present invention;

[0037] Fig.12 is the chromatogram of isoquercetin of the present invention;

[0038] Fig.13 This is the chromatogram of notoginsenoside R1 of the present invention;

[0039] Fig.14 This is the chromatogram of ginsenoside Rg1 of the present invention;

[0040] Fig.15 This is the chromatogram of dragon's blood A of the present invention;

[0041] Fig.16 This is the pterostilbene chromatogram of the present invention;

[0042] Fig.17 This is the chromatogram of dehydrocostus lactone of the present invention;

[0043] Fig.18 is the chromatogram of inulin lactone of the present invention;

[0044] Fig.19 is the chromatogram of 11-carbonyl-β-acetyl boswellic acid of the present invention;

[0045] Fig. 20 This is the mass spectrum of Zhanjin Huoxue Powder of the present invention in positive ion mode;

[0046] Fig.21 This is the mass spectrum of Zhanjin Huoxue Powder of the present invention in negative ion mode.

[0047] Fig. 22 is the mass spectrum of curcuma dione / curcumol of the present invention;

[0048] Fig.23 is the mass spectrum of t-cadinol of the present invention;

[0049] Fig.24 This is the mass spectrum of pomelo peel of the present invention;

[0050] Fig.25 This is the mass spectrum of dragon's blood B of the present invention;

[0051] Fig.26 This is the mass spectrum of ginsenoside Rb1 of the present invention;

[0052] Fig. 27 This is the mass spectrum of palmitoleic acid of the present invention;

[0053] Fig.28 This is the mass spectrum of pterostilbene of the present invention;

[0054] Fig.29 This is the mass spectrum of hyodeoxycholic acid / deoxycholic acid of the present invention;

[0055] Fig.30 This is the mass spectrum of 11-carbonyl-β-boswellic acid of the present invention;

[0056] Fig.31 is the mass spectrum of musk ketone of the present invention;

[0057] Fig.32 This is the mass spectrum of 9-methoxybisabolone of the present invention;

[0058] Fig.33 This is the mass spectrum of dehydrocostus lactone of the present invention;

[0059] Fig.34 This is the mass spectrum of dragon's blood A of the present invention;

[0060] Fig.35 The mass spectrum of inulin lactone / costunolide of the present invention;

[0061] Fig.36 This is the mass spectrum of 3-acetyl-α-boswellic acid / 3-acetyl-β-boswellic acid of the present invention;

[0062] Fig.37 This is the mass spectrum of 11-carbonyl-β-acetylboswellic acid of the present invention;

[0063] Fig.38 This is the mass spectrum of α-boswellic acid / β-boswellic acid of the present invention;

[0064] Fig.39 This is the characteristic spectrum of 15 batches of Zhanjin Huoxue Powder test samples of the present invention. DETAILED DESCRIPTION

[0065] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.

[0066] It should be noted that the process equipment or devices not specifically specified in the following embodiments are all conventional equipment or devices in the art.

[0067] It should be noted that the terms "include" and "have" and any variations thereof are intended to cover non-exclusive inclusions. For example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices. Moreover, unless otherwise specified, the numbering of each method step is only a convenient tool for identifying each method step, and is not intended to limit the order of arrangement of each method step or to define the scope of the present invention. Changes or adjustments in their relative relationships should also be regarded as the scope of the present invention without substantially changing the technical content.

[0068] 1. A method for constructing a characteristic spectrum of Zhanjin Huoxue Powder comprises the following steps:

[0069] S1. Weigh appropriate amounts of the contents of Zhanjin Huoxue Powder from different batches, add methanol, and perform ultrasonic extraction to obtain a Zhanjin Huoxue Powder test solution;

[0070] S2, dissolving ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, rutin, notoginsenoside R1, hyperoside, rutin, resveratrol, 11-carbonyl-β-acetyl boswellic acid in methanol to obtain a single reference solution;

[0071] S3, inject the test solution in S1 and the reference solution in S2 into a high performance liquid chromatograph for chromatographic analysis, perform detection under the same conditions, and record the chromatograms of the test solution and the reference solution;

[0072] S4. The test solution is subjected to high-resolution mass spectrometry analysis to obtain a total ion current diagram, and the total ion current diagram is imported into Xcalibur software. Data analysis is performed according to the peak conditions of the chromatogram of the test solution to obtain mass spectrum result diagrams of various chemical components. A total of 15 chemical components are analyzed through high-resolution mass spectrometry analysis of the material benchmark of Zhanjin Huoxue Powder, and combined with the HPLC-MS component analysis results of 10 medicinal material extracts of ginseng, amber, myrrh, frankincense, dragon's blood, pearl powder, angelica, Panax notoginseng, artificial musk, and artificial bezoar in the preparation prescription in the early stage of the present invention, the 15 chemical components are attributed and analyzed. The results showed that 9-methoxybisabolone, dehydrocostus lactone, inulin lactone and costus lactone were derived from myrrh; pterostilbene and dragon's blood A were derived from dragon's blood; 3-acetyl-α-boswellic acid, 3-acetyl-β-boswellic acid, 11-carbonyl-β-acetylboswellic acid, α-boswellic acid, β-boswellic acid and 11-carbonyl-β-boswellic acid were derived from frankincense; musk ketone was derived from artificial musk; hyodeoxycholic acid and deoxycholic acid were derived from artificial bezoar;

[0073] S5. Import the chromatograms of the test solutions and reference solutions of different batches of Zhan Jin Huo Xue San obtained in S3 into the Chinese Medicine Chromatographic Characteristic Spectrum Similarity Evaluation System (2004A Version); select the chromatographic peaks existing in the chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San as common peaks, generate the reference spectrum of Zhan Jin Huo Xue San by the average value calculation method, and calculate the relative retention time and relative peak area of ​​each common peak; perform similarity analysis after data import, multi-point correction and data matching; obtain and export the similarity result table between the chromatograms of the test solutions of Zhan Jin Huo Xue San from different batches and the common peak pattern; confirm the reliability of the result based on the similarity result table and the chromatogram of the test solution of Zhan Jin Huo Xue San.

[0074] S6. According to the chromatogram of the test solution of Zhanjin Huoxue Powder and the chromatogram of the single reference solution obtained in S3, and in combination with the total ion flow diagram obtained by high-resolution mass spectrometry and the mass spectrum result diagram of the chemical components, a comparison is performed, and resveratrol (peak 17) is used as the reference peak. Peak 9 in the chromatogram is identified as rutin, peak 10 as hyperoside, peak 11 as isoquercetin, peak 12 as notoginseng saponin R1, peak 16 as ginsenoside Rg1, peak 31 as dragon's blood A, peak 34 as pterostilbene, peak 37 as dehydrocostus lactone, peak 39 as inulin lactone, and peak 53 as 11-carbonyl-β-acetylboswellic acid, to obtain the characteristic spectrum of Zhanjin Huoxue Powder.

[0075] Resveratrol (peak 17), dragon's blood A (peak 31), and pterostilbene (peak 34) are derived from dragon's blood; rutin (peak 9), hyperoside (peak 10), isoquercetin (peak 11), and notoginseng saponin R1 (peak 12) are derived from Panax notoginseng; ginsenoside Rg1 (peak 16) is derived from ginseng; dehydrocostus lactone (peak 37) and inulin lactone (peak 39) are derived from myrrh; 11-carbonyl-β-acetylboswellic acid (peak 53) is derived from frankincense.

[0076] Among them, the preparation method of the Zhanjin Huoxue Powder test solution in S1 is preferably: weigh 0.2 g of the contents of 15 batches of Zhanjin Huoxue Powder respectively, place them in a stoppered conical flask, add 10 mL of methanol, ultrasonically extract for 45 minutes, filter, and pass the filtrate through a 0.45 μm microporous filter membrane twice to obtain the Zhanjin Huoxue Powder test solution.

[0077] The method for preparing the standard solution in S2 is preferably: accurately weigh ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, inulin lactone, notoginsenoside R1, hyperoside, rutin, and resveratrol respectively and dissolve them in methanol solution to prepare a single reference solution containing 0.82 mg of ginsenoside Rg1, 0.99 mg of dehydrocostus lactone, 0.87 mg of pterostilbene, 0.57 mg of isoquercetin, 0.59 mg of dragon's blood A, 0.99 mg of inulin lactone, 0.52 mg of notoginsenoside R1, 0.65 mg of hyperoside, 0.96 mg of rutin, 0.41 mg of resveratrol, and 0.97 mg of 11-carbonyl-β-acetylboswellic acid per 1 mL.

[0078] The liquid chromatography conditions in S3 are: chromatographic column: Shim-pack VP-ODS (250 mm × 4.6 mm, 5 μm) chromatographic column; detector: diode array detector, detection wavelength is 210 nm; volume flow rate: 1.0 mL / min; injection volume: 10 μL; mobile phase: acetonitrile (A)-0.1% phosphoric acid aqueous solution (B), gradient elution, elution program is shown in Table 1:

[0079] Table 1 Liquid chromatography elution program

[0080]

[0081] In S4, the high-resolution mass spectrometry detection conditions were: electrospray ionization, spray voltage 3500 V, sheath gas flow rate 40 arb, auxiliary gas flow rate 10 arb, capillary temperature 300°C, auxiliary gas temperature 300°C, scanning mode was full scan mode, and the mass-to-charge ratio scanning range m / z was 100-1300.

[0082] 2. Optimization process of feature map detection:

[0083] S1. Optimization of test solution preparation:

[0084] The present invention experimentally investigated different extraction methods (ultrasound, reflux, immersion), and the results are as follows Figure 2 As shown, the results showed that the chromatogram obtained by ultrasonic extraction had more comprehensive components and good separation, so the ultrasonic extraction method was adopted.

[0085] The present invention compares the extraction effects of different extraction solvents (water, ethanol, methanol, 50% methanol solution, 70% methanol solution), and the results are as follows: Figure 3 As shown, the results showed that when pure methanol was used as the extraction solvent, the extract chromatogram had the most information and the highest component content, so pure methanol was selected for extraction.

[0086] The present invention compares the extraction effects of different extraction times (30min, 45min, 1h), and the results are as follows Figure 4 As shown, the results showed that the chromatogram obtained when ultrasonic extraction was performed for 45 minutes had the highest component content, good peak shape, and high separation, so 45 minutes was selected as the ultrasonic extraction time.

[0087] S2. Optimize the chromatographic conditions:

[0088] The present invention uses a diode array detector to investigate the detection wavelength and extracts the chromatograms at 275nm, 254nm, 230nm, and 210nm. The results are as follows: Figure 5 As shown, it was found that when the detection wavelength condition was 210 nm, the chromatogram contained the most comprehensive information and the baseline was stable, so this method was selected as the detection wavelength condition.

[0089] The present invention screened the column temperature (25°C, 30°C, 35°C), and the results were as follows Figure 6 As shown in the results, it was found that when the column temperature was maintained at 30°C, the peak elution was optimal and the separation effect of each component was better, so the column temperature of 30°C was finally selected.

[0090] The present invention compares the elution effects of different elution systems under different gradients, such as acetonitrile-0.1% phosphoric acid, methanol-water, acetonitrile-water, and methanol-0.1% phosphoric acid. Figure 7 As shown, the results showed that when acetonitrile-0.1% phosphoric acid was used as the mobile phase, the separation effect of the components in Zhanjin Huoxue Powder was better, so acetonitrile-0.1% phosphoric acid was finally selected as the mobile phase.

[0091] After determining the optimal mobile phase composition, the present invention screened the best gradient elution program through a large number of experiments, and some elution programs are as follows:

[0092] Table 2 Elution program 1

[0093]

[0094] Table 3 Elution program 2

[0095]

[0096]

[0097] Table 4 Elution procedure 3

[0098]

[0099] Table 5 Elution Program 4

[0100]

[0101] Table 6 Elution Program 5

[0102]

[0103] Table 7 Elution Program 6

[0104]

[0105]

[0106] Test results such as Figure 8 As shown. Figure 8 It can be seen that elution program 6 has good separation, high peak height, stable baseline, and complete chromatographic information. Therefore, elution program 6 is selected as the optimal elution program.

[0107] The embodiments of the present invention are described in detail below with reference to the examples. If no specific conditions are specified in the examples, the experiments are carried out according to conventional conditions or conditions recommended by the manufacturer. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be obtained commercially.

[0108] The instruments and reagents used in the embodiments are as follows:

[0109] Experimental equipment

[0110] 1. The instruments used in the present invention are shown in Table 8.

[0111] Table 8 Instruments and reagents used in the present invention

[0112]

[0113] 2. Drugs and reagents

[0114] The different batches of Zhanjin Huoxue powder samples used in the present invention are all purchased from the market and are all produced by Shaanxi Momed Qixuehe Pharmaceutical Co., Ltd.

[0115] The reagents used in the present invention are shown in Table 9.

[0116] Table 9 Reagents used in the present invention

[0117]

[0118] Reference substances: ginsenoside Rg1 reference substance (batch number: 110703-202436, purity: 97%), dehydrocostus lactone reference substance (batch number: 111525-202313, purity: 99.8%), isoquercetin (batch number: 111809-202205, purity: 96.3%), dragon's blood A reference substance (batch number: 111660-202403, purity: 99.8%), scutellaria lactone reference substance (batch number: 110760-201811, purity: 99.4%), notoginsenoside R1 reference substance (batch number: 110745-202322, purity: 97.8%), hyperoside reference substance (batch number: 111521-202310, purity: 94.7%), rutin reference substance (batch number: 100080-202012, purity: 92.2%), resveratrol reference substance (batch number: 111535-201703, purity: 99.4%), and 11-carbonyl-β-acetylboswellic acid (batch number: 111760-202103, purity: 91.3%) were all purchased from China Food and Drug Inspection Institutes; pterostilbene reference substance (batch number: P815984, purity: 98%) was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.

[0119] Embodiment 1 A method for constructing a characteristic spectrum of Zhanjin Huoxue Powder comprises the following steps:

[0120] S1. Preparation of Zhanjin Huoxue Powder test solution:

[0121] Weigh 0.2 g of the contents of 15 batches of Zhanjin Huoxue Powder respectively, put them into a stoppered conical flask, add 10 mL of methanol, perform ultrasonic extraction for 45 min, filter, and pass the filtrate through a 0.45 μm microporous filter membrane twice to obtain the Zhanjin Huoxue Powder test solution.

[0122] S2. Preparation of reference solution:

[0123] Accurately weigh ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, inulin, notoginsenoside R1, hyperoside, rutin, and resveratrol and dissolve them in methanol to prepare a single reference solution containing 0.82 mg of ginsenoside Rg1, 0.99 mg of dehydrocostus lactone, 0.87 mg of pterostilbene, 0.57 mg of isoquercetin, 0.59 mg of dragon's blood A, 0.99 mg of inulin, 0.52 mg of notoginsenoside R1, 0.65 mg of hyperoside, 0.96 mg of rutin, 0.41 mg of resveratrol, and 0.97 mg of 11-carbonyl-β-acetylboswellic acid per 1 mL.

[0124] S3, inject the test solution in S1 and the reference solution in S2 into the high performance liquid chromatograph for chromatographic analysis, perform the test under the same conditions, and record the chromatogram of the test solution ( Fig.39 ) and the chromatogram of the reference solution ( Figure 9-Figure 19 );

[0125] The liquid chromatography conditions were as follows: chromatographic column: Shim-pack VP-ODS (250 mm × 4.6 mm, 5 μm) chromatographic column; detector: diode array detector, detection wavelength was 210 nm; volume flow rate: 1.0 mL / min; injection volume: 10 μL; mobile phase: acetonitrile (A)-0.1% phosphoric acid aqueous solution (B), gradient elution, the elution program is shown in Table 1.

[0126] S4, the test solution is subjected to high-resolution mass spectrometry analysis to obtain a total ion current diagram ( Figure 20-21 ), the total ion flow chart was imported into Xcalibur software, and data analysis was performed according to the peaks of the chromatogram of the test solution to obtain the mass spectrum result chart of each chemical component ( Figure 22-Figure 38 );

[0127] The high-resolution mass spectrometry detection conditions were as follows: electrospray ionization, spray voltage 3500 V, sheath gas flow rate 40 arb, auxiliary gas flow rate 10 arb, capillary temperature 300°C, auxiliary gas temperature 300°C, full scan mode, and mass-to-charge ratio scanning range m / z 100-1300.

[0128] S5. Import the chromatograms of the test solutions and reference solutions of 15 batches of Zhanjin Huoxue Powder obtained in S3 into the Chinese Medicine Chromatographic Characteristic Spectrum Similarity Evaluation System (2004A Version); select the chromatographic peaks existing in the chromatograms of the test solutions of different batches of Zhanjin Huoxue Powder as common peaks, generate the reference spectrum of Zhanjin Huoxue Powder by the average value calculation method, and calculate the relative retention time and relative peak area of ​​each common peak; perform similarity analysis after data import, multi-point correction and data matching; obtain and export the similarity result table between the chromatograms of the test solutions of different batches of Zhanjin Huoxue Powder and the common peak pattern; confirm the reliability of the result based on the similarity result table and the chromatogram of the test solution of Zhanjin Huoxue Powder.

[0129] S6. According to the chromatogram of the test solution of Zhanjin Huoxue Powder and the chromatogram of the single reference solution obtained in S3, combined with the total ion flow diagram obtained by high-resolution mass spectrometry and the mass spectrum result diagram of the chemical components, resveratrol (peak 17) was used as the reference peak, and peak 9 in the chromatogram was identified as rutin, peak 10 as hyperoside, peak 11 as isoquercetin, peak 12 as notoginseng saponin R1, peak 16 as ginsenoside Rg1, peak 31 as dragon's blood A, peak 34 as pterostilbene, peak 37 as dehydrocostus lactone, peak 39 as inulin lactone, and peak 53 as 11-carbonyl-β-acetyl boswellic acid, and the characteristic spectrum of Zhanjin Huoxue Powder was obtained ( Figure 1 ).

[0130] At the same time, the present invention uses the automatically generated reference spectrum R to generate a common chromatographic peak pattern, and the analysis and calculation show that the common chromatographic peaks of 15 batches of Zhanjin Huoxue Powder test samples have relatively good similarity, indicating that the characteristic spectrum of Zhanjin Huoxue Powder established by this method can well detect the quality of Zhanjin Huoxue Powder and 15 batches of Zhanjin Huoxue Powder. The results are shown in Table 10.

[0131] Table 10 Similarity between each batch of samples and the common chromatographic peak pattern

[0132]

[0133] Example 2 Methodological study of characteristic spectrum detection method:

[0134] S1. Precision study

[0135] The test solution prepared by the method of Example 1 was taken and analyzed according to the detection method of Example 1. The samples were injected in parallel 6 times with an injection volume of 10 μL. Ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, scutellaria lactone, notoginseng saponin R1, hyperoside, rutin and resveratrol were used as reference peaks. The peak area and retention time were analyzed and the RSD value was calculated. The results showed that the RSD of the relative retention time was less than 0.23%, and the RSD of the relative peak area was less than 2.11%, indicating that the parallel injection precision of the equipment was good.

[0136] S2. Stability study

[0137] The test solution prepared by the method of Example 1 was taken and analyzed according to the detection method of Example 1. The sample was injected and analyzed at different times of 0, 2, 6, 12, 18, and 24 h, and the injection volume was 10 μL. Ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, scutellaria lactone, notoginseng saponin R1, hyperoside, rutin, resveratrol, and 11-carbonyl-β-acetylboswellic acid were used as reference peaks. The peak area and retention time of the common peaks of the HPLC characteristic spectrum of the sample were analyzed and the RSD value was calculated. The results showed that the RSD of the relative retention time was less than 0.17%, and the RSD of the relative peak area was less than 2.28%, indicating that the chromatographic peak of the test solution of Zhanjin Huoxue Powder within 24 h had almost no change and good stability.

[0138] S3. Reproducibility study

[0139] Six batches of sample solutions were prepared according to the test solution method in Example 1, with reference to the chromatographic conditions of Example 1, with an injection volume of 10 μL, and ginsenoside Rg1, dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, scutellaria lactone, notoginseng saponin R1, hyperoside, rutin, resveratrol, and 11-carbonyl-β-acetylboswellic acid as reference peaks. The peak area and retention time of the common peaks of the HPLC characteristic spectrum of the samples were analyzed and the RSD values ​​were calculated. The results showed that the RSD of the relative retention time was less than 0.19%, and the RSD of the relative peak area was less than 2.12%, indicating that the sample chromatographic peak reproducibility was good and the method had good repeatability.

[0140] The above experimental results show that the characteristic spectrum construction method of Zhanjin Huoxue Powder provided by the present invention has the characteristics of good stability, high precision and good repeatability, can comprehensively and objectively evaluate the quality of Zhanjin Huoxue Powder, and provide quality assurance for clinical efficacy.

[0141] The above embodiments are only exemplary embodiments of the present invention and are not intended to limit the present invention. The protection scope of the present invention is defined by the claims. The above contents are only used as examples and explanations of the concept of the present invention. Various modifications or supplements made by technicians in the technical field to the described specific embodiments or replacements in similar ways shall fall within the protection scope of the present invention as long as they do not deviate from the concept of the invention or exceed the scope defined by the claims.

Claims

1. The construction method of the characteristic map of Zhanjin Huoxue Powder, It is characterized in that The following steps are involved: S1. Take the contents of Zhanjin Huoxue Powder, add methanol, and perform ultrasonic extraction to obtain a test solution; S2. Extract ginsenoside Rg 1 , dehydrocostus lactone, pterostilbene, isoquercetin, dragon's blood A, scutellaria lactone, notoginseng saponin R 1 , hyperoside, rutin, resveratrol, and 11-carbonyl-β-acetylboswellic acid were dissolved in methanol to obtain a single reference solution; S3, injecting the test solution in S1 and the reference solution in S2 into a high performance liquid chromatograph for chromatographic analysis, and recording the chromatograms of the test solution and the reference solution; S4, performing high-resolution mass spectrometry analysis on the test solution to obtain a total ion current diagram, importing the total ion current diagram into Xcalibur software, performing data analysis based on the peaks of the chromatogram of the test solution, and obtaining mass spectrum result diagrams of each chemical component; S5. According to the chromatogram of the test solution and the chromatogram of the single reference solution, the chemical composition of each peak in the chromatogram of the test solution is determined in combination with the total ion current diagram and the mass spectrum of the chemical components to obtain a characteristic spectrum.

2. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that The ultrasonic extraction time is 30min-1h.

3. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that In S3, the liquid chromatography conditions are as follows: the chromatographic column is a Shim-pack VP-ODS chromatographic column; and the detection wavelength of the detector is 210 nm.

4. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that In S3, the liquid chromatography conditions are as follows: the mobile phase is acetonitrile-0.1% phosphoric acid aqueous solution.

5. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that In S3, the liquid chromatography conditions are: gradient elution, and the elution program is shown in the following table: 。 6. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that Also includes: The chromatograms of the test solutions of different batches of Zhanjin Huoxue Powder obtained in S3 were imported into the Chinese medicine chromatographic characteristic spectrum similarity evaluation system and subjected to similarity analysis to confirm the reliability of the results.

7. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 5, It is characterized in that The chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San obtained in S3 are imported into the Chinese medicine chromatographic characteristic spectrum similarity evaluation system and similarity analysis is performed to confirm the reliability of the results, specifically: the chromatograms of the test solutions and reference solutions of different batches of Zhan Jin Huo Xue San obtained in S3 are imported into the Chinese medicine chromatographic characteristic spectrum similarity evaluation system; the chromatographic peaks existing in the chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San are selected as common peaks, and the reference spectrum of Zhan Jin Huo Xue San is generated by the average value calculation method, and the relative retention time and relative peak area of ​​each common peak are calculated; after data import, multi-point correction and data matching, similarity analysis is performed; the similarity result table between the chromatograms of the test solutions of different batches of Zhan Jin Huo Xue San and the common peak pattern is obtained and exported; the reliability of the results is confirmed based on the similarity result table and the chromatogram of the test solution of Zhan Jin Huo Xue San.

8. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that In S4, the high-resolution mass spectrometry detection conditions were: electrospray ionization, spray voltage 3500 V, sheath gas flow rate 40 arb, auxiliary gas flow rate 10 arb, capillary temperature 300°C, auxiliary gas temperature 300°C, scanning mode was full scan mode, and the mass-to-charge ratio scanning range m / z was 100-1300.

9. The method for constructing the characteristic spectrum of Zhanjin Huoxue Powder according to claim 1, It is characterized in that In S5, based on the chromatogram of the test solution and the chromatogram of the single reference solution obtained in S3, combined with the total ion flow obtained by high-resolution mass spectrometry and the mass spectrum of the chemical components, resveratrol was used as the reference peak, and peak 9 in the chromatogram was identified as rutin, peak 10 as hyperoside, peak 11 as isoquercetin, and peak 12 as notoginsenoside R. 1 , Peak 16 is ginsenoside Rg 1 , peak No. 31 is dragon's blood A, peak No. 34 is pterostilbene, peak No. 37 is dehydrocostus lactone, peak No. 39 is inulin lactone, peak No. 53 is 11-carbonyl-β-acetylboswellic acid, and the characteristic spectrum of Zhanjin Huoxue Powder is obtained.

10. The characteristic spectrum of Zhanjin Huoxue Powder constructed by the method described in any one of claims 1 to 9.